Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies
A Strzelczyk, S Schubert-Bast - CNS drugs, 2022 - Springer
The developmental and epileptic encephalopathies encompass a group of rare syndromes
characterised by severe drug-resistant epilepsy with onset in childhood and significant …
characterised by severe drug-resistant epilepsy with onset in childhood and significant …
Developmental and epileptic encephalopathies: what we do and do not know
N Specchio, P Curatolo - Brain, 2021 - academic.oup.com
Developmental encephalopathies, including intellectual disability and autistic spectrum
disorder, are frequently associated with infant epilepsy. Epileptic encephalopathy is used to …
disorder, are frequently associated with infant epilepsy. Epileptic encephalopathy is used to …
Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial
KG Knupp, IE Scheffer, B Ceulemans… - JAMA …, 2022 - jamanetwork.com
Importance New treatment options are needed for patients with Lennox-Gastaut syndrome
(LGS), a profoundly impairing, treatment-resistant, developmental and epileptic …
(LGS), a profoundly impairing, treatment-resistant, developmental and epileptic …
DBS of thalamic centromedian nucleus for Lennox–Gastaut syndrome (ESTEL trial)
Objective Prior uncontrolled studies have reported seizure reductions following deep brain
stimulation (DBS) in patients with Lennox–Gastaut syndrome (LGS), but evidence from …
stimulation (DBS) in patients with Lennox–Gastaut syndrome (LGS), but evidence from …
Emerging use of epidiolex (cannabidiol) in epilepsy
R Abu-Sawwa, B Scutt, Y Park - The Journal of Pediatric …, 2020 - meridian.allenpress.com
The first plant-derived, purified pharmaceutical-grade cannabidiol (CBD) medication,
Epidiolex, was approved in the United States by the FDA on June 25, 2018. Its approval for …
Epidiolex, was approved in the United States by the FDA on June 25, 2018. Its approval for …
Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial
AD Patel, M Mazurkiewicz‐Bełdzińska, RF Chin… - …, 2021 - Wiley Online Library
Summary Objective Lennox–Gastaut syndrome (LGS) is an epileptic encephalopathy that is
often treatment resistant. Efficacy and safety of add‐on cannabidiol (CBD) to treat seizures …
often treatment resistant. Efficacy and safety of add‐on cannabidiol (CBD) to treat seizures …
A phase 2, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet …
CD Hahn, Y Jiang, V Villanueva, M Zolnowska… - …, 2022 - Wiley Online Library
Objective Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS) are rare treatment‐
resistant childhood epilepsies classed as developmental and epileptic encephalopathies …
resistant childhood epilepsies classed as developmental and epileptic encephalopathies …
Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
E Thiele, E Marsh, M Mazurkiewicz‐Beldzinska… - …, 2019 - Wiley Online Library
Summary Objective Patients with Lennox‐Gastaut syndrome (LGS) who completed 1 of 2
randomized, double‐blind, placebo‐controlled trials of add‐on cannabidiol …
randomized, double‐blind, placebo‐controlled trials of add‐on cannabidiol …
A comprehensive review of emerging trends and innovative therapies in epilepsy management
Epilepsy is a complex neurological disorder affecting millions worldwide, with a substantial
number of patients facing drug-resistant epilepsy. This comprehensive review explores …
number of patients facing drug-resistant epilepsy. This comprehensive review explores …
An emerging role for sigma-1 receptors in the treatment of developmental and epileptic encephalopathies
P Martin, T Reeder, J Sourbron, PAM de Witte… - International journal of …, 2021 - mdpi.com
Developmental and epileptic encephalopathies (DEEs) are complex conditions
characterized primarily by seizures associated with neurodevelopmental and motor deficits …
characterized primarily by seizures associated with neurodevelopmental and motor deficits …